Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention (“CDC”) adopted new ...

Medical staff in Western Australia have been warned after reports of the wrong immunisations being given to patients.

The Food and Drug Administration has approved three vaccines for RSV — GSK's GSK.L Arexvy, Moderna's MRNA.O mRESVIA and ...

The Department of Health has sent an urgent reminder to medical staff to make sure they’re giving patients the right RSV ...

Canada hosted ITF Masters events in Mont-Tremblant and Ottawa over the past month, with the hosts dominating the latter.

Find patient medical information for Abrysvo (respiratory syncytial virus vaccine) on WebMD including its uses, side effects and safety, interactions, pictures, warnings, and user ratings ...

A newly configured federal vaccine panel's June 25 action is expected to improve options to protect infants from potentially ...

This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the ...

Today, Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory Syncytial Virus (RSV) in older adults in Canada for 2024-2025.

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

First assessment from an RSV vaccine study in immunocompromised adults show ABRYSVO was well-tolerated and generated strong neutralizing responses after a single dose in adults ≥ 18 years of age ...

This release contains forward-looking information about ABRYSVO, including its potential benefits and a vote by ACIP to expand its recommendation to include adults 50-59 years of age at increased ...